BioCina Appoints Dr. Thomas Broudy as Chief Executive Officer
Dr. Broudy brings over 20 years of experience in the biopharmaceutical and CDMO industries to lead BioCina's growth in biologic drug substance and sterile drug product development and manufacturing services. As Chairman of BioCina's Board of Directors, Dr. Broudy has been instrumental in shaping the company's vision and providing operational leadership to the drug substance and drug product businesses.
Key Takeaways:
- Dr. Thomas Broudy has been appointed as Chief Executive Officer of BioCina, bringing over 20 years of experience in the biopharmaceutical and CDMO industries.
- Dr. Broudy has a technical background, having held postdoctoral appointments at Rockefeller University and Stanford University, and earned his PhD at Rockefeller in the Laboratory of Bacterial Pathogenesis and Immunology.
- Prior to his appointment, Dr. Broudy served as Chairman of BioCina's Board of Directors and Operating Partner of Bridgewest Group's life sciences portfolio.
- BioCina has recently announced the merger of its Adelaide-based drug substance facility and its Perth-based commercial sterile drug product facility, providing customers with a one-stop shop for drug substance and drug product-clinical to commercial.
- BioCina is a global end-to-end biologics and small molecule Contract Development and Manufacturing Organization (CDMO), offering the highest-quality, cost-effective clinical and commercial drug substance and sterile drug product manufacture.
- Bridgewest Group is an innovative and privately held global investment firm with over $3B in private capital, founded in 1999 and based in the US.
Statistics:
- BioCina has over 20 years of experience in the biopharmaceutical and CDMO industries through Dr. Broudy's leadership.
- Dr. Broudy has a background spanning the full drug development value chain, including executive roles at both innovative biotech and outsourced service providers.
- BioCina's services span development and clinical and commercial manufacturing for microbial, pDNA, mRNA, and LNP-based products, and sterile filling of small and large molecule products in multiple formats.
- Bridgewest Group has $3B in private capital and has been investing in key sectors such as Life Sciences, Software, Semiconductor, and Artificial Intelligence/Deep Tech since 1999.
Sources:
- BioCina press release, October 28, 2025
- Bridgewest Group website, About page
- Dr. Thomas Broudy's LinkedIn profile, October 28, 2025
- Rockefeller University, Department of Laboratory of Bacterial Pathogenesis and Immunology